AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28856960 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Oriented Training and Evaluation at Home (TOTE Home) program, 30 sessions of 1 hour each
Number of subjects: 4
Study 28857778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 901
Study 28857822 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based antiretroviral therapy (ART)
Number of subjects: 103
Study 28857936 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential anal RFA using Barrx 60 RFA focal catheters, median duration of treatment 6.5 minutes (range 5-13 minutes).
Number of subjects: 10
Study 28858441 — intervention group
Group type: EXPERIMENTAL
Intervention: THINC-integrated tool (THINC-it)
Number of subjects: 100
Study 28858443 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram monotherapy
Number of subjects: 2280
Study 28858564 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography with image processing algorithms
Number of subjects: 31
Study 28858898 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless handheld ultrasound with pattern recognition software (Accuro)
Number of subjects: 47
Study 28858898 — intervention group
Group type: COMPARATOR
Intervention: Tuohy needle depth to epidural space
Number of subjects: 47
Study 28859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy (1.8 to 1.3 mg/m2 for cycle 1 followed by 1.3 to 1.0 mg/m2 for subsequent cycles).
Number of subjects: 59
Study 28859185 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy.
Number of subjects: 59
Study 28859325 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-remission (mean PGA 3.6, s.d. 1.9)
Number of subjects: 1588
Study 28859325 — intervention group
Group type: COMPARATOR
Intervention: Non-remission
Number of subjects: 1588
Study 28859325 — intervention group
Group type: COMPARATOR
Intervention: Remission
Number of subjects: 1588
Study 28859622 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group (positive for anti-HPA antibody)
Number of subjects: 55497
Study 28859622 — intervention group
Group type: COMPARATOR
Intervention: Non-exposure group (negative for anti-HPA antibody)
Number of subjects: 55497
Study 28859648 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) intervention including in-person outpatient palliative care consultation and telephonic nurse coach sessions with monthly calls.
Number of subjects: 61
Study 28859794 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-Based Primary Prevention Implantable Cardioverter-Defibrillator
Number of subjects: 0
Study 28859794 — intervention group
Group type: COMPARATOR
Intervention: Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator
Number of subjects: 0
Study 28860107 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples' HIV counseling and testing plus dyadic adherence counseling
Number of subjects: 330
Study 28860107 — intervention group
Group type: COMPARATOR
Intervention: Individual HIV counseling and testing
Number of subjects: 330
Study 28860229 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of the appropriateness of oral anticoagulant prescriptions developed from hospital information systems.
Number of subjects: 80
Study 28860229 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi consensus method for assessing utility and operational implementation of selected indicators.
Number of subjects: 80
Study 28860229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional study to assess the ability of indicators to detect inappropriate oral anticoagulant prescriptions.
Number of subjects: 80
Study 28860229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools for transferring indicators into other institutions.
Number of subjects: 80
Study 28860342 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 monotherapy
Number of subjects: 37
Study 28860342 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 with rituximab
Number of subjects: 37
Study 28860342 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 in MYC-altered DLBCL patients
Number of subjects: 37
Study 28860342 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 in MYC unaltered DLBCL patients
Number of subjects: 37
Study 28860342 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 in patients with unknown MYC status
Number of subjects: 37
Study 28860342 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 overall
Number of subjects: 37
Study 28861121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg daily for 24 weeks
Number of subjects: 83
Study 28861121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 28862132 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28862547 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional management (first RCT)
Number of subjects: 107
Study 28862547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preembolization as an adjunct to surgery or radiotherapy (second RCT)
Number of subjects: 107
Study 28862547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgment alone (registry)
Number of subjects: 107
Study 28862547 — intervention group
Group type: COMPARATOR
Intervention: Surgery (first RCT)
Number of subjects: 107
Study 28862877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg intravenous dose)
Number of subjects: 0
Study 28862877 — intervention group
Group type: COMPARATOR
Intervention: Segmental allergen challenge without mepolizumab
Number of subjects: 0
Study 28862936 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid magnetic resonance imaging (CMRI) for detecting high-risk plaques (HRP)
Number of subjects: 1047
Study 28862936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum wall thickness measurement
Number of subjects: 1047
Study 28862950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic cycle training for 12 weeks
Number of subjects: 73
Study 28862959 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceval sutureless aortic valve bioprosthesis
Number of subjects: 47
Study 28862963 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with STEMI (delayed care)
Number of subjects: 6022
Study 28862963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delays from symptom onset to hospital presentation of ≤1 hour
Number of subjects: 6022
Study 28862970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FFR (≤0.80)
Number of subjects: 1024
Study 28862970 — intervention group
Group type: COMPARATOR
Intervention: High FFR (>0.80)
Number of subjects: 1024
Study 28862971 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828
Study 28862971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828
Study 28863021 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° head rotation toward the ipsilateral side
Number of subjects: 41
Study 28863021 — intervention group
Group type: COMPARATOR
Intervention: 30° head rotation toward the contralateral side
Number of subjects: 41
Study 28863021 — intervention group
Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 41
Study 28863021 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral 30° head rotation
Number of subjects: 41
Study 28863143 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct spoligotyping on sputum
Number of subjects: 199
Study 28863143 — intervention group
Group type: COMPARATOR
Intervention: Indirect spoligotyping on cultures
Number of subjects: 199
Study 28863143 — intervention group
Group type: COMPARATOR
Intervention: Ancestral lineages (including M. africanum Lineages 5 and 6)
Number of subjects: 199
Study 28863143 — intervention group
Group type: COMPARATOR
Intervention: Lineage 5
Number of subjects: 199
Study 28863143 — intervention group
Group type: COMPARATOR
Intervention: Lineage 4
Number of subjects: 199
Study 28863774 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention intervention
Number of subjects: 0
Study 28863774 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28864403 — intervention group
Group type: EXPERIMENTAL
Intervention: TomoTherapy
Number of subjects: 166
Study 28864403 — intervention group
Group type: COMPARATOR
Intervention: RapidArc
Number of subjects: 166
Study 28864814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 added to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for cGVHD.
Number of subjects: 24
Study 28865109 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Program (WL)
Number of subjects: 0
Study 28865109 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (M)
Number of subjects: 0
Study 28865109 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Program (WL) + Moxonidine (WL + M)
Number of subjects: 0
Study 28865448 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme™
Number of subjects: 240
Study 28865448 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Q®
Number of subjects: 240
Study 28865448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® Aura-i™
Number of subjects: 240
Study 28866036 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 141
Study 28866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild absolute increase in SCr (0.25 to 0.50mg/dl)
Number of subjects: 3091
Study 28866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild relative increase in SCr (25% to 50%)
Number of subjects: 3091
Study 28866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate increase in SCr (0.5 to 1.0mg/dl)
Number of subjects: 3091
Study 28866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing renal dysfunction (eGFR<60ml/min)
Number of subjects: 3091
Study 28866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Large increase in SCr (>1.0mg/dl)
Number of subjects: 3091
Study 28866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall post-procedural increases in SCr (mild, moderate, large)
Number of subjects: 3091
Study 28866290 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV (2 doses for unprimed, 1 dose for primed)
Number of subjects: 52
Study 28866290 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age-matched children)
Number of subjects: 52
Study 28866726 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 week course of antibiotics
Number of subjects: 45
Study 28866726 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week course of antibiotics
Number of subjects: 45
Study 28866726 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-SPECT/CT at 12 weeks
Number of subjects: 45
Study 28866779 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral poliovirus vaccine (OPV)
Number of subjects: 315
Study 28866779 — intervention group
Group type: COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 315
Study 28867340 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-order contextual learning task
Number of subjects: 0
Study 28867416 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Skills (ERSQ) in MUS patients
Number of subjects: 458
Study 28867416 — intervention group
Group type: COMPARATOR
Intervention: Emotion Regulation Skills (ERSQ) in MDD and MUS+MDD groups
Number of subjects: 458
Study 28867416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediating effect of depression and anxiety in MUS groups
Number of subjects: 458
Study 28867665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral baclofen (dosage not specified)
Number of subjects: 49
Study 28868035 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28869617 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan, dosage not specified, duration not specified
Number of subjects: 0
Study 28869617 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28869790 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0
Study 28869790 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in HER2-positive patients
Number of subjects: 0
Study 28869790 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in tumours with Ki-67 ≥ 15%
Number of subjects: 0
Study 28869790 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in tumours with Ki-67 < 15%
Number of subjects: 0
Study 28869931 — intervention group
Group type: EXPERIMENTAL
Intervention: PXD-101 followed by Zevalin
Number of subjects: 5
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Total screen viewing time (SVT) at age 2
Number of subjects: 910
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing time at age 2
Number of subjects: 910
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held device viewing time at age 2
Number of subjects: 910
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held device SVT at age 3
Number of subjects: 910
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking of SVT from age 2 to 3
Number of subjects: 910
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: SVT by ethnicity at age 2
Number of subjects: 910
Study 28870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of longer SVT
Number of subjects: 910
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARTgirl membership
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk for ATS use disorder
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HIV care
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month retention in care
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of STI symptoms
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse symptoms of psychological distress
Number of subjects: 88
Study 28870232 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater numbers of sex partners
Number of subjects: 88
Study 28870448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal IL-25 protein level in NP tissues
Number of subjects: 42
Study 28870448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal IL-25 protein level
Number of subjects: 42
Study 28870448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tissue IL-25
Number of subjects: 42
Study 28870611 — intervention group
Group type: EXPERIMENTAL
Intervention: TargomiRs (miR-16-based mimic microRNA) administered via 20 min intravenous infusion either once or twice a week in a traditional 3+3 dose-escalation design in five dose cohorts.
Number of subjects: 27
Study 28870611 — intervention group
Group type: EXPERIMENTAL
Intervention: TargomiRs
Number of subjects: 27
Study 28870615 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (0.75-1.75 mg/kg)
Number of subjects: 58
Study 28870615 — intervention group
Group type: COMPARATOR
Intervention: Luspatercept (0.125-0.5 mg/kg)
Number of subjects: 58
Study 28870615 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 58
Study 28870716 — intervention group
Group type: EXPERIMENTAL
Intervention: MobiusHD device implanted unilaterally in the internal carotid artery
Number of subjects: 30
Study 28870792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with 11 Gy × 3 hypofractionated stereotactic reirradiation
Number of subjects: 15
Study 28870792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with 10 Gy × 3 hypofractionated stereotactic reirradiation
Number of subjects: 15
Study 28870792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with 9 Gy × 3 hypofractionated stereotactic reirradiation
Number of subjects: 15
Study 28871029 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with service users
Number of subjects: 0
Study 28871029 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with clinicians
Number of subjects: 0
Study 28871238 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using the Traffic Light System (TLS)
Number of subjects: 30
Study 28871238 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 28871238 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using the TLS
Number of subjects: 30
Study 28871441 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb® adsorber applications (1 to 5 applications)
Number of subjects: 198
Study 28871441 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb® adsorber applications
Number of subjects: 198
Study 28871961 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 661
Study 28871961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine strains
Number of subjects: 661
Study 28872399 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants living more than 3 miles from work
Number of subjects: 292
Study 28872399 — intervention group
Group type: COMPARATOR
Intervention: Participants living within 3 miles of work
Number of subjects: 292
Study 28872399 — intervention group
Group type: COMPARATOR
Intervention: Urban participants
Number of subjects: 292
Study 28872399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonurban participants
Number of subjects: 292
Study 28872549 — intervention group
Group type: EXPERIMENTAL
Intervention: Zr-trastuzumab PET/CT
Number of subjects: 20
Study 28873076 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation using electroencephalogram monitoring during a constant level of sedation depth (D0 to D2) performed by trained nurses or physicians after a body-weight-adjusted loading dose.
Number of subjects: 219
Study 28873076 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 219
Study 28873128 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) as PrEP for 48 weeks
Number of subjects: 78
Study 28873162 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal tumor-normal sequencing
Number of subjects: 1040
Study 28874132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers in patients on maintenance dialysis
Number of subjects: 157
Study 28874132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers
Number of subjects: 157
Study 28874132 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH levels
Number of subjects: 157
Study 28874132 — intervention group
Group type: COMPARATOR
Intervention: Fractured patients
Number of subjects: 157
Study 28874132 — intervention group
Group type: COMPARATOR
Intervention: Fracture prevalence
Number of subjects: 157
Study 28874164 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR fluoroscopy guided right heart catheterization
Number of subjects: 39
Study 28874545 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV)
Number of subjects: 0
Study 28874545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin combined with TIV
Number of subjects: 0
Study 28874669 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived primary cultures (PDCs) for head and neck squamous cell carcinomas
Number of subjects: 2
Study 28874669 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive '-omics' interrogation of PDCs
Number of subjects: 2
Study 28874669 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response in patient-derived models
Number of subjects: 2
Study 28875153 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-load exercise (PHLE)
Number of subjects: 100
Study 28875153 — intervention group
Group type: COMPARATOR
Intervention: Low-load exercise (LLE)
Number of subjects: 100
Study 28877563 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT/EVT (n=22, IVT n=15, IVT+EVT n=3, EVT n=4)
Number of subjects: 114
Study 28877563 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT
Number of subjects: 114
Study 28877563 — intervention group
Group type: EXPERIMENTAL
Intervention: DNT
Number of subjects: 114
Study 28877563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding
Number of subjects: 114
Study 28877664 — intervention group
Group type: EXPERIMENTAL
Intervention: BETACONNECT® autoinjector for IFN beta-1b
Number of subjects: 143
Study 28877684 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (not specified in detail, but includes nicotine replacement therapy or other cessation aids offered to 42% of smokers)
Number of subjects: 1083
Study 28877684 — intervention group
Group type: COMPARATOR
Intervention: Unemployed or disability benefits
Number of subjects: 1083
Study 28877684 — intervention group
Group type: COMPARATOR
Intervention: Low education
Number of subjects: 1083
Study 28877684 — intervention group
Group type: COMPARATOR
Intervention: Longer smoking duration
Number of subjects: 1083
Study 28877684 — intervention group
Group type: COMPARATOR
Intervention: Not having ST-elevation myocardial infarction (STEMI) as index event
Number of subjects: 1083
Study 28877684 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial factors at follow-up
Number of subjects: 1083
Study 28877684 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation for cessation
Number of subjects: 1083
Study 28877684 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk perception of tobacco use
Number of subjects: 1083
Study 28877686 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA combined with valproic acid and possibly low-toxicity conventional chemotherapy (low-dose cytarabine, hydroxyurea, 6-mercaptopurin)
Number of subjects: 43
Study 28877686 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 43
Study 28877686 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and valproic acid
Number of subjects: 43